Evidence map›Paper›PMID 41995149›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo.

Fernanda V Cabral, Jose Quilez-Alburquerque, Olivia Mooradian, Shivendran Vytheswarran, Badri Parshad, Girgis Obaid, Huang-Chiao Huang, Tayyaba Hasan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fernanda V CabralWellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6247-2220
Jose Quilez-AlburquerqueWellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Olivia MooradianWellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Shivendran VytheswarranWellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Badri ParshadWellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Girgis ObaidDepartment of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.ORCID https://orcid.org/0000-0002-9452-4467
Huang-Chiao HuangFischell Department of Bioengineering, College Park, University of Maryland, Maryland, MD, USA.ORCID https://orcid.org/0000-0002-5406-0733
Tayyaba HasanWellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0871-6057

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Brian William Pogue · 2001 to 2026
$27.9M
Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor LiposomeR01CA260340 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2021 to 2025
$3.2M
Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic PrimingR01EB034360 · NIBIB · UNIVERSITY OF TEXAS DALLAS · PI Girgis Obaid · 2024 to 2026
$1.6M
NCI NIH HHS P01 CA084203NCI NIH HHS R01 CA260340NIBIB NIH HHS R01 EB034360NIH HHS P01CA084203NIH HHS R01CA260340NIH HHS R01EB034360
6 · The paper itself

Abstract

Overcoming drug resistance in pancreatic ductal adenocarcinoma (PDAC) remains a major challenge due to dense fibrotic stroma, DNA repair-mediated resistance, drug efflux mechanisms, and an immunosuppressive tumor microenvironment (TME). Here, we use photoactivatable multi-inhibitor liposomes (PMILs) as a clinically translatable strategy to immunomodulate and enhance PDAC treatment using FDA-approved agents: minocycline for tumor priming by downregulating Tdp1, benzoporphyrin derivative incorporated into the liposomal bilayer for photodynamic priming (PDP) of the microenvironment, and irinotecan (IRI) for cytotoxicity. PMILs enable light-triggered PDP followed by IRI release. The reduced Tdp1 combined with PDP and IRI acts synergistically to enhance antitumor activity. In an orthotopic PDAC mouse model, dual priming significantly increased intratumoral IRI accumulation while downregulating Tdp1 and ABCG2, two key mediators of IRI resistance. These effects were augmented by immune activation, including increased CD8

Indexed as

Carcinoma, Pancreatic DuctalDrug Resistance, NeoplasmMinocyclinePancreatic NeoplasmsPhotochemotherapyTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalHumansIrinotecanMiceIrinotecanMinocyclineantitumor immune activationminocycline primingpancreatic cancerphotodynamic primingtumor microenvironment remodeling

Identifiers

PMID41995149
PMCPMC13334859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.